| ID | 10110 |
| Vaccine Name | AMBIRIX |
| Disease Name | Hepatitis A, Hepatitis B |
| Disease Classification | Hepatitic |
| Virus Name | Hepatitis A, Hepatitis B virus |
| Nucleic Acid Content | double stranded DNA |
| Vaccine Type | Inactivated |
| Vaccine Status | Approved |
| Manufacturer | GlaxoSmithKline |
| Year of Manufacturing | 2002 |
| Manufacturing Country | Belgium |
| Age | 2 - 15 years |
| Dosage | 2 doses 6 to 12 months apart |
| Administration Route | Intramuscular |
| Adjuvant | Aluminum (aluminum phosphate) |
| Target Strain | Inactivated hepatitis A virus and surface antigen of hepatitis B virus |
| Description | Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology |
| Approving Organisation | EMA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NA |
| Reference Link | https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf |
| Additional Links | https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|